Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655120 | 0.88 | MAPT (0.46) | GPR119MAPTKDM4ETHRBPTPN2 | |
| SCHEMBL23306598 | 0.82 | KDM4E (0.53) | GPR119MAPTKDM4ETHRBPTPN2 | |
| SCHEMBL3122923 | 0.81 | GPR119 (0.54) | GPR119 | |
| SCHEMBL13521274 | 0.81 | LMNA (0.44) | MAPTTHRBPOLBHPGD | |
| SCHEMBL3897024 | 0.81 | KDM4E (0.52) | GPR119MAPTKDM4ETHRBDDB1 | |
| SCHEMBL13521311 | 0.79 | CCNE1 (0.46) | CCNE1CDK2 | |
| SCHEMBL3118835 | 0.79 | GPR119 (0.51) | GPR119 | |
| SCHEMBL30872409 | 0.79 | KDM4E (0.50) | GPR119MAPTKDM4ETHRBDDB1 | |
| SCHEMBL3241101 | 0.78 | GPR119 (0.59) | GPR119MAPTTHRBPOLBJAK3 | |
| SCHEMBL3122663 | 0.77 | GPR119 (0.48) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-119654315-A | 3- (6-Pyridin-3-yl) -2- [4- (4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl ] benzonitrile derivatives and similar compounds as QPCTL and QPCT inhibitors for the treatment of cancer | 858治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| CN-110719910-A | Novel inhibitors | 前体生物药物股份公司 | 2020-01-21 | — | — | CN | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | GPR119 833/4885MAPT 3890/4885KDM4E 1773/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | GPR119 856/4885MAPT 2845/4885KDM4E 1119/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | GPR119 950/4885MAPT 2831/4885KDM4E 1078/4885 |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | GPR119 2440/4885MAPT 411/4885KDM4E 1604/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | GPR119 1048/4885MAPT 1850/4885KDM4E 1254/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | GPR119 989/4885MAPT 3042/4885KDM4E 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.